探索慢性淋巴细胞白血病的发病路径
本文综述慢性淋巴细胞白血病(CLL)的生物学研究进展,指出基于IGHV序列突变状态可将CLL分为未突变(U)和突变(M)两型,二者在细胞起源、生物学、表观遗传学/遗传学及临床行为上各具特征。U-CLL起源于天然抗体库,IGHV1-69优势提示超抗原驱动;两型中自身抗原刺激肿瘤细胞形成动态循环,但M-CLL中增殖与无反应性的平衡偏向无反应性。尽管靶向治疗取得进展,细胞逃逸、Richter转化和免疫抑制仍是挑战。
要点
- 基于IGHV序列突变状态将CLL分为U-CLL和M-CLL两型,二者细胞起源和临床行为不同。
- U-CLL起源于天然抗体库,IGHV1-69优势提示超抗原驱动。
- 自身抗原刺激肿瘤细胞形成动态循环,M-CLL中平衡偏向无反应性。
核心结论
- CLL应基于IGHV序列突变状态分为U-CLL和M-CLL两型,各具独特细胞起源、生物学、表观遗传学/遗传学和临床行为。
- 尽管对肿瘤细胞生物学的认识带来治疗改善,细胞逃逸、Richter转化和免疫抑制仍是挑战。
研究设计与样本
- 本文为综述,总结CLL生物学研究进展及其对评估和治疗的影响。
主要发现
- U-CLL起源于天然抗体库,IGHV1-69优势揭示超抗原驱动。
- U-CLL和M-CLL中自身抗原刺激肿瘤细胞形成动态重复循环,细胞免于凋亡并在血液与组织间迁移。
- M-CLL中增殖与无反应性的平衡偏向无反应性,两型结局不同。
- 微环境相互作用调节反应,T细胞辅助的可及性可能是细胞命运决定因素,其依赖程度在U-CLL和M-CLL间不同。
临床怎么用
- 基于IGHV序列突变状态将CLL分为U-CLL和M-CLL两型以指导评估。
- 关注肿瘤细胞对表面免疫球蛋白受体信号、生存通路和微环境辅助细胞的依赖,设计靶向治疗。
局限性
- 细胞逃逸策略、Richter转化和免疫抑制仍是挑战,需继续研究CLL生物学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In chronic lymphocytic leukemia (CLL), increasing knowledge of the biology of the tumor cells has led to transformative improvements in our capacity to assess and treat patients. The dependence of tumor cells on surface immunoglobulin receptor signaling, survival pathways, and accessory cells within the microenvironment has led to a successful double-barreled attack with designer drugs. Studies have revealed that CLL should be classified based on the mutational status of the expressed IGHV sequences into 2 diseases, either unmutated (U) or mutated (M) CLL, each with a distinctive cellular origin, biology, epigenetics/genetics, and clinical behavior. The origin of U-CLL lies among the natural antibody repertoire, and dominance of IGHV1-69 reveals a superantigenic driver. In both U-CLL and M-CLL, a calibrated stimulation of tumor cells by self-antigens apparently generates a dynamic reiterative cycle as cells, protected from apoptosis, transit between blood and tissue sites. But there are differences in outcome, with the balance between proliferation and anergy favoring anergy in M-CLL. Responses are modulated by an array of microenvironmental interactions. Availability of T-cell help is a likely determinant of cell fate, the dependency on which varies between U-CLL and M-CLL, reflecting the different cells of origin, and affecting clinical behavior. Despite such advances, cell-escape strategies, Richter transformation, and immunosuppression remain as challenges, which only may be met by continued research into the biology of CLL.
引用
- Stevenson FK, Forconi F, Kipps TJ, et al. Exploring the pathways to chronic lymphocytic leukemia. Blood. 2021. PMID: 34075408. doi:10.1182/blood.2020010029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。